The preclinical assessment of the risk for QT interval prolongation

Therapie

Volumn 55, Issue 1, 2000, Pages 101-109

  Champeroux, P ^a   Martel, E ^a   Vannier, C ^a   Blanc, V ^a   Leguennec, J Y ^b   Fowler, J ^c   Richard, S ^a  

^a CERB   (France)

^b CNRS   (France)

^c The Ship   (United Kingdom)

Author keywords

Electrocardiogram; Preclinical assessment; Proarrhythmic risk; Purkinje fibres; QT interval prolongation

Indexed keywords

ASTEMIZOLE; CISAPRIDE; SPARFLOXACIN;

CONFERENCE PAPER; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART PAPILLARY MUSCLE; NONHUMAN; PRIORITY JOURNAL; PURKINJE FIBER; QT INTERVAL; RISK ASSESSMENT; TECHNIQUE; TORSADE DES POINTES;

ANIMALS; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT;

EID: 0034067414     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Caron J, Adamantididis MM, Bordet R et al. Effets proarrhythmiques des antihistaminiques H1. La lettre du Pharmacologue 1996; 10: 200-207.
2. Adamantidis MM, Kerram P, Dupuis BA. In vitro electrophysiological detection of iatrogenic arrhythmogenicity. Fundam Clin Pharmacol 1994; 8: 391-407.
3. Committee for Proprietary Medicinal Products. The Assessment of the Potential for QT Interval Prolongation by Non-cardiovascular Medicinal Products, CPMP 986/96. London: European Agency for the Evaluation of Medicinal Products 1997.
4. Adamantidis MM, Lacroix DL, Caron JF et al. Electrophysiological and arrhythmogenic effects of the histamine type-1 receptor antagonist astemizole on rabbit Purkinje fibres: clinical relevance. J Cardiovas Pharmacol 1995; 26: 319-327.
5. Salata JJ, Jurkiewicz NK, Wallace AA et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1994; 76: 110-119.
6. Carlsson L, Amos GJ, Andersson B et al. Electrophysiological characterisation of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential. J Pharmacol Exp Ther 1997; 282: 220-227.
7. Adamantidis MM, Dumontier BM, Caron JF et al. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarisation in rabbit Purkinje fibres. Fundam Clin Pharmacol 1998; 12: 70-76.
8. Lang DG, Wang CM, Wenger TL. Terfenadine alters action potentials in isolated canine Purkinje fibers more than acrivastine. J Cardiovasc Pharmacol 1993; 22: 438-442.
9. Michiels M, Van Peer A, Woestenborghs R et al. Pharmacokinetics and tissue distribution of astemizole in the dog. Drug Dev Res 1986; 8: 53-62.
10. Saviuc P, Danel V, Dixmerias F, Prolonged QT interval and Torsades de Pointes following astemizole overdose. J Toxicol Clin Toxicol 1993; 31: 121-125.
11. Roden D, Lazzara R, Rozen M et al. Multiple mechanisms in the QT long syndrome. Current knowledge, gaps and future directions. Circulation 1996; 94: 1996-2012.
12. Moss AJ, Zareba W, Benhorin J et al. ECG-T wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-2934.
13. Koh KK, Rim MS, Yoon J et al. Torsades de Pointes induced by terfenadine in a patient with long QT syndrome. J Electrocardiol 1994; 27: 343-346.
14. Weissenburger J. Le syndrome de QT long: une affaire de canal sodique? La lettre du Pharmacologue 1996; 10: 208-209.
15. Detweiler DK. Electrocardiography in toxicological studies. In: 'Sipes IG, McQueen CA Gandolfi AJ eds. Comprehensive Toxicology. Amsterdam, Netherlands: Elsevier 1997; 6: 95-115.
16. Matsunaga T, Mitsui T, Harada T et al. QT corrected for heart rate and relation between QT and RR intervals in Beagle dogs. J Pharmacol Toxicol Methods 1997; 38: 201-209.
17. Sarma JSM, Sarma RJ, Bilitch M et al. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: re-evaluation of Bazett's formula. Am Heart J 1984; 54: 103-108.
18. Usui T, Sugiyama A, Ishida Y et al. Simultaneous assessment of the haemodynamic, cardiomechanical and electrophysiological effects of terfenadine on the in vivo canine model. Heart Vessels 1998; 13: 49-57.
19. Chezaviel F, Weissenburger J, Davy JM. Proarrhythmic effects of a quinidine analog in dogs with chronic A-V block. Fundam Clin Pharmacol 1995; 9: 240-247.
20. Weissenburger J, Davy JM, Chezaviel F. Experimental models of Torsades de Pointes. Fundam Clin Pharmacol 1993; 7: 29-38.
21. Hey JA, Del Prado M, Kreutner W et al. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental model of Torsades de Pointes. Arzneim Forsch Drug Res 1996; 46: 159-163.
22. Bluth JD, Lappi MD, Billman GE. Effect of terfenadine on cardiac electrical properties and susceptibility to arrhythmias in animals with healed myocardial infarction. FASEB J 1994; 8: A77.
23. Davis AS. The pre-clinical assessment of QT interval prolongation: a comparison of in vitro and in vivo methods. Hum Exp Toxicol 1998; 17: 677-680.
24. Jaillon P, Dupuis B, Dahan R et al. Etudes electrophysiologiques pré-cliniques eu vue de la prédiction d'un effet proarrhythmique (torsades de pointes) iatrogène. Therapie 1997; 52: 271-280.